Andreas Pahl, Uwe Oelmller,* and Susanne
Ullmann*
Department of Pharmacology, University of Erlangen, Erlangen, Germany
* QIAGEN GmbH, Hilden Germany
Drug library screening based on gene expression
analysis requires reliable and reproducible methods of RNA purification
and sensitive, quantitative, real-time RT-PCR analysis. This article demonstrates
how RNeasy 96 technology, automated on the BioRobot Gene Expression
workstation, enabled reproducible, high-throughput sample preparation. One-step,
real-time RT-PCR using the QuantiTect Probe RT-PCR Kit provided highly
sensitive gene expression
analysis to identify potential drugs to fight asthma.
Bronchial asthma is one of the commonest chronic diseases in modern society
and the most common chronic childhood disease. The pathogenesis and causes
of asthma are still poorly understood. Nonetheless, our knowledge of asthma
pathogenesis has increased greatly over the past two decades, partially
through recognition of the critical role played by cytokines in the inflammatory
response.
Many cytokines are involved in asthma. Although some of these cytokines
are involved in many inflammatory diseases, others are more specific to
allergic
inflammation, such as asthma. These cytokines include interleukins (IL)
IL-4 and IL-13, which are derived from T-helper 2 (Th2) cells. Th1 cells,
which are involved in cellular immunity, secrete other cytokines, such as
IL-2. Gene expression analysis of these cytokines provides valuable information
about the effects of potential drugs for asthma.
The goal of our research is to identify potential new drugs that selectively
inhibit expression of specific cytokines. High-throughput RNeasy 96 RNA
isolation technology automated on the BioRobot Gene Expression workstation
and real-time RT-PCR analysis using the QuantiTect Probe RT-PCR Kit enable
sensitive analysis of cytokine gene expression. These technologies speed
the progresstoward new specific drugs to fight asthma.
Materials and methods
Peripheral blood monocytes (PBMCs) were grown in 96-well plates with 200,000
cells per well. The cells were treated with different drug candidates for
30 minutes. TPA/ Ionomycin was then added to stimulate Th1 and Th2 cells,
and the cells were incubated for a further 4 hours. Unstimulated cells were
used as a control for basal gene expression levels. The cell cultures were
then placed on the BioRobot Gene Expression workstation for fully automated
RNA purification using the RNeasy 96 BioRobot 8000 Kit. Quantitative, real-time
RT-PCR of cytokine transcripts was carried out in 384-well format on the
ABI PRISM 7900HT Sequence Detection System using the QuantiTect Probe
RT-PCR Kit.
Results and discussion
Automated RNA isolation on the BioRobot Gene Expression workstation and
quantification by one-step, real-time QuantiTect Probe RT-PCR enable creening
of large numbers of synthetic and natural substances for their effects on
cytokine expression in cells. We have used this approach to screen for asthma
drugs that inhibit expression of Th2-specific cytokines (1). Figure 1 shows
an example using cyclosporine A (CSA), which was used as a control compound
during the screening process. CSA is an immunosuppressive agent known to
inhibit transcription of IL-2 and used to prevent organ transplant rejection.
Expression
of IL-2 mRNA was essentially inhibited by treatment with CSA. Expression
of Th2 specific IL-13 mRNA was reduced to a lesser extent in the CSA-treated
cells, and IL-4 mRNA expression was the same in unstimulated cells and CSA-treated
cells, indicating that the drug prevented the stimulation-dependent increase
in gene expression. Expression of -actin mRNA, used as a housekeeping
transcript control, remained unchanged.
High-Throughput Screening of Cytokine Expression
Figure 1 PBMCs were stimulated with TPA/lonomycin or unstimulated,
and treated with CSA or not treated, as indicated (see Materials
and
methods). Total RNA was isolated using RNeasy 96 technology,
fully
automated on the BioRobot Gene Expression workstation. Real-time,
quantitative, one-step RT-PCR was carried out in a 384-well format
using
the QuantiTect Probe RT-PCR Kit and primers and probes specific for
the
transcripts indicated. All reactions were carried out with 2 to 4
replicates.
Threshold cycles are indicated.
Conclusions
- Fully automated RNeasy 96 technology on the BioRobot Gene Expression
workstation enabled walkaway operation for high throughput drug screening
applications.
- Quantitative, real-time, one-step RT-PCR using the QuantiTect Probe
RT-PCR Kit provided highly sensitive results to analyze expression of
different cytokines in response to drug candidates.
- High-throughput drug screening using these technologies enables identification
of specific potential drugs to combat asthma.
Reference
1. Pahl, A. (2002)
Manuscript in
preparation.
'"/>Source:
Page: All 1 2 3 4 Related biology technology :1.
Quantitative end-point RT-PCR gene
expression measurement using the
Agilent 2100 Bioanalyzer and
standardized RT-PCR2.
Laser Capture Microdissection of muscle fiber populations and expression analysis by RT-PCR3.
Cytosolic expression of Green Fluorescent Protein (GFP) and its derivatives
in the yeast Saccharomyces cerevisiae: Detection in vivo using
the Varian Cary Eclipse4.
Successful stabilization of gene expression profiles5.
Fully automated DNA purification and efficient multiplex PCR for analysis
of microsatellite loci6.
Flow cytometric analysis of human
primary cells using the Agilent 2100
bioanalyzer and on-chip staining7.
2100 expert software
Powerful software for the analysis of RNA, DNA, proteins, and cells with the Agilent 2100 bioanalyzer8.
Using the Agilent 2100 bioanalyzer for
quality control of protein samples prior to
MS-analysis9.
Microfluidic analysis of multiplex
PCR products for the genotyping of
Helicobacter pylori10.
High resolution DNA analysis with the
DNA 500 and DNA 1000 LabChip kits11.
Extended data analysis using DeCyder EDA